The pharmaceutical industry has seen a tremendous surge in the development of weight loss drugs, particularly GLP-1 receptor ...

According to the Congressional Budget Office, the average 2034 per-user effect could be $650 in savings and $4,300 in costs ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk (NVO) and Eli Lilly (LLY) by introducing GLP-1 pills.

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

Sipping on this popular beverage may help you reach your weight-loss goals. From lemon water to apple-cider vinegar shots, there is an endless number of trendy drinks ... If eating healthier and ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a ...

If you or someone you know has diabetes, you’ve likely heard of metformin, a drug that’s primarily prescribed to support ...

Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

Still, more than a quarter of employers are considering adding coverage for GLP-1 drugs for weight loss in 2025 or 2026, according to a national survey conducted this year by Mercer, a human resources ...